Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug-induced liver disease.

James H Lewis1, Moustafa Ahmed, Ahmed Shobassy

  • 1Division of Gastroenterology, Georgetown University Medical Center, Washington DC 20007, USA. lewisjh@gunet.georgetown.edu

Current Opinion in Gastroenterology
|March 22, 2006
PubMed
Summary

Acetaminophen and tuberculosis drugs remain common causes of drug-induced liver injury (DILI). DILI is a significant cause of acute liver failure, necessitating further research into risk factors for safer drug use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Liver Safety of the Dual Neurokinin‑1/‑3 Receptor Antagonist Elinzanetant.

Drug safety·2026
Same author

Liver Safety of the Dual Neurokinin-1/-3 Receptor Antagonist Elinzanetant.

Drug safety·2026
Same author

Hepatic Effects, Potential Drug-Induced Liver Injury, and Other Liver Safety Considerations of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in the New Era of Expanding Non-oncology Indications: Literature Review and Expert Consensus.

Drug safety·2025
Same author

Modifying Hy's Law and eDISH for the modern idiosyncratic DILI era.

Expert opinion on drug metabolism & toxicology·2025
Same author

The Impact of COVID-19 and COVID-19 Vaccination on Detection, Assessment, and Management of Suspected Acute Drug-Induced Liver Injury Occurring during Clinical Trials: Consensus Recommendations from the IQ DILI Initiative.

Drug safety·2025
Same author

Managing Aminotransferase Elevations in Patients with Friedreich Ataxia Treated with Omaveloxolone: A Review and Expert Opinion on Use Considerations.

Neurology and therapy·2025

Area of Science:

  • Hepatology
  • Clinical Pharmacology
  • Toxicology

Background:

  • Drug-induced liver disease (DILI) is a significant concern in clinical practice.
  • Understanding the agents and risk factors for DILI is crucial for patient safety.

Purpose of the Study:

  • To review clinical, histological, epidemiological, and mechanistic features of DILI reported in 2005.
  • To summarize common causative agents and clinical outcomes of DILI.

Main Methods:

  • Review of case reports, case series, and clinical studies published in 2005.
  • Analysis of epidemiological data and clinical presentations of DILI.

Main Results:

  • Acetaminophen, highly active antiretroviral therapy (HAART), and tuberculosis drugs were most frequently reported causes of DILI.

Related Experiment Videos

  • Acetaminophen is the leading cause of acute liver failure in the USA.
  • Hy's Law was supported, with at least 10% of acute drug-induced hepatocellular jaundice cases leading to death or transplant.
  • Statins and second-generation thiazolidinediones were found safe in patients with elevated baseline liver enzymes.

    • Conclusions:

    • DILI remains an important cause of acute liver failure.
    • Ongoing research aims to identify risk factors and host susceptibilities for safer drug utilization.
    • Further investigation is needed to mitigate the risks associated with DILI.